全文获取类型
收费全文 | 16870篇 |
免费 | 857篇 |
国内免费 | 344篇 |
专业分类
耳鼻咽喉 | 123篇 |
儿科学 | 142篇 |
妇产科学 | 50篇 |
基础医学 | 1829篇 |
口腔科学 | 1791篇 |
临床医学 | 1246篇 |
内科学 | 1314篇 |
皮肤病学 | 112篇 |
神经病学 | 1350篇 |
特种医学 | 530篇 |
外科学 | 3353篇 |
综合类 | 2195篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 946篇 |
眼科学 | 268篇 |
药学 | 2013篇 |
15篇 | |
中国医学 | 349篇 |
肿瘤学 | 440篇 |
出版年
2023年 | 191篇 |
2022年 | 273篇 |
2021年 | 700篇 |
2020年 | 505篇 |
2019年 | 567篇 |
2018年 | 593篇 |
2017年 | 456篇 |
2016年 | 518篇 |
2015年 | 534篇 |
2014年 | 1072篇 |
2013年 | 1022篇 |
2012年 | 957篇 |
2011年 | 1012篇 |
2010年 | 807篇 |
2009年 | 734篇 |
2008年 | 624篇 |
2007年 | 582篇 |
2006年 | 585篇 |
2005年 | 450篇 |
2004年 | 407篇 |
2003年 | 343篇 |
2002年 | 263篇 |
2001年 | 216篇 |
2000年 | 189篇 |
1999年 | 150篇 |
1998年 | 141篇 |
1997年 | 137篇 |
1996年 | 117篇 |
1995年 | 97篇 |
1994年 | 90篇 |
1993年 | 72篇 |
1992年 | 72篇 |
1991年 | 64篇 |
1990年 | 52篇 |
1989年 | 39篇 |
1988年 | 48篇 |
1987年 | 44篇 |
1985年 | 297篇 |
1984年 | 382篇 |
1983年 | 343篇 |
1982年 | 421篇 |
1981年 | 457篇 |
1980年 | 327篇 |
1979年 | 307篇 |
1978年 | 176篇 |
1977年 | 173篇 |
1976年 | 161篇 |
1975年 | 110篇 |
1974年 | 67篇 |
1973年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
2.
目的::研究股骨近端空心锁定板内固定治疗股骨颈骨折的临床效果。方法:对2008年2月至2010年4月我院入院治疗的108例股骨颈骨折患者进行了研究,随机分为两组,对照组给与空心钉进行治疗,观察组采用股骨近端空心锁定板内固定治疗,比较两组治疗方案的手术时间、出血量、住院时间以及下床时间,比较两组治疗方案的手术并发症发生率,并比较两组患者三年期临床疗效。结果:观察组患者手术出血量明显少于对照组,手术时间、住院时间以及下床时间明显短于对照组,两组比较差异明显,有统计学意义( P<0.05);两组患者手术并发症均以疼痛、骨不连以及感染为主,其中观察组上述并发症的发生率为13.0%,明显低于对照组33.3%,两组比较差异有统计学意义( P<0.05);观察组患者三年临床总有效率为79.6%,对照组患者三年期临床总有效率为51.9%,两组比较差异明显,有统计学意义( P<0.05)。结论:股骨近端空心锁定板内固定治疗股骨颈骨折临床效果显著,可以明显缩短手术时间以及住院时间,降低手术并发症,并且三年临床总有效率更高,值得临床推广应用。 相似文献
3.
文题释义:肱骨近端骨折:肱骨近端包括肱骨头及大结节、小结节,中老年人骨质疏松及低能量损伤可导致肱骨近端骨折。
同种异体腓骨:取自于人体异体,经过加工处理,去除其免疫原性,保留其骨性结构,可用于移植修复骨缺损,起到支撑作用。
背景:肱骨近端骨折是临床常见骨折,但对肱骨近端内侧柱缺乏支撑的骨折目前仍是治疗难点,并发症常见,失败率较高。
目的:比较解剖锁定钢板联合同种异体腓骨与单纯解剖锁定钢板治疗肱骨近端骨折的疗效。
方法:使用计算机检索PubMed、Embase、Cochrane Library、Google Scholar、中国知网、万方、维普数据库,检索时间均从建库到2020年2月。检索国内外关于对比研究解剖锁定钢板联合同种异体腓骨与单纯解剖锁定钢板治疗肱骨近端骨折疗效的文献。2名研究员根据纳入和排除标准分别独立筛选文献,提取数据,评估文献中的偏倚风险。纳入12篇相关文献使用RevMan 5.2软件将以下指标进行Meta分析,包括影像学数据、功能评分和并发症。结果与结论:①通过文献检索、根据纳入和排除标准,12篇文献纳入研究,其中11篇为回顾性队列研究,1篇为随机对照研究;纳入研究文献质量高,但GRADE证据质量级别较低。②共纳入958例患者,其中解剖锁定钢板联合同种异体腓骨组411例,单纯解剖锁定钢板组547例;③Meta分析结果显示,解剖锁定钢板联合同种异体腓骨组术后1年肱骨头高度差值(MD=-2.40,95%CI:-2.49至-2.31)、颈干角差值(MD= -6.14,95%CI:-6.62至-5.67)、目测类比评分(MD=-0.22,95%CI:-0.35至-0.08)、肩关节功能评分(MD=4.12,95%CI:2.18-6.06),上肢伤残评分(MD=-10.32,95%CI:-13.44至-7.19)、术后2年的目测类比评分(MD=-0.37,95%CI:-0.55至-0.19)、肩关节功能评分(MD=5.07,95%CI:2.86-7.27)、总体并发症(OR=0.31,95%CI:0.20-0.48)及肱骨头螺钉切出(OR=0.25,95%CI:0.11-0.55)均明显优于单纯解剖锁定钢板组(P < 0.05),肱骨头坏死(OR=0.94,95%CI:0.47-1.88),两组间差异无显著性意义(P > 0.05);④因此,较弱的证据提示,肱骨近端解剖锁定钢板联合同种异体腓骨治疗肱骨近端骨折的短期疗效优于解剖锁定钢板,可减少并发症的发生,促进功能恢复。ORCID: 0000-0002-8486-3932(阳运康)
中国组织工程研究杂志出版内容重点:人工关节;骨植入物;脊柱;骨折;内固定;数字化骨科;组织工程 相似文献
4.
《International journal of oral and maxillofacial surgery》2020,49(7):914-931
Titanium osteosynthesis is currently the fixation system of choice in maxillofacial traumatology. Biodegradable osteosynthesis systems have the ability to degrade in the human body. The aim of this study was to conduct a systematic review, with meta- and trial sequential analyses, to assess the efficacy and morbidity of biodegradable versus titanium osteosynthesis after maxillofacial trauma. MEDLINE, Embase, and CENTRAL were searched for randomized controlled trials and prospective and retrospective controlled studies. Five time periods were studied: perioperative, short-term (0–4 weeks), intermediate (6–12 weeks), long-term (>12 weeks), and overall follow-up. After screening 3542 records, 24 were included. All had a high risk of performance and detection bias due to the nature of the interventions. Meta-analysis showed no differences in efficacy or morbidity between biodegradable and titanium osteosynthesis. The risk of perioperative screw breakage was significantly higher (risk ratio 17.13, 95% confidence interval 2.19–34.18) and the symptomatic plate removal rate lower in the biodegradable group (risk ratio 0.11, 95% confidence interval 0.02–0.57), which was confirmed by the trial sequential analysis. The quality of evidence ranged from very low to moderate. Based on the narrative review and meta-analyses, current evidence shows that biodegradable osteosynthesis is a viable alternative to titanium osteosynthesis when applied in the treatment of maxillofacial trauma, with similar efficacy but significantly lower symptomatic plate removal rates. Perioperative screw breakage occurred significantly more often in the biodegradable group compared to the titanium group. 相似文献
5.
By means of the ultrasonic surface impact (amplitude of 30 μm, strike number of 48,000 times/mm2), nanograins have been achieved in the surfaces of both Ti6Al4V(TC4) and Ti3Zr2Sn3Mo25Nb(TLM) titanium alloys, mainly because of the dislocation motion. Many mechanical properties are improved, such as hardness, residual stress, and roughness. The rotating–bending fatigue limits of TC4 and TLM subjected to ultrasonic impact are improved by 13.1% and 23.7%, separately. Because of the bending fatigue behavior, which is sensitive to the surface condition, cracks usually initiate from the surface defects under high stress amplitude. By means of an ultrasonic impact tip with the size of 8 mm, most of the inner cracks present at the zone with a depth range of 100~250 μm in the high life region. The inner crack core to TC4 usually appears as a deformed long and narrow α-phase, while the cracks in TLM specimens prefer to initiate at the triple grain boundary junctions. This zone crosses the grain refined layer and the deformed coarse grain layer. With the gradient change of elastic parameters, the model shows an increase of normal stress at this zone. Combined with the loss of plasticity and toughness, it is easy to understand these fatigue behaviors. 相似文献
6.
目的探讨不同手术方法治疗复杂胫骨平台骨折临床疗效。方法选择2016年1月—2018年12月84例复杂胫骨平台骨折患者,随机分组。单侧锁定钢板内固定组选择单侧锁定钢板内固定手术,双侧切口双侧解剖钢板内固定组选择双侧切口双侧解剖钢板内固定。分析手术操作时间、手术失血、平均住院天数以及复杂胫骨平台骨折愈合时间;治疗前后患者视觉模拟评分和Rasmussen膝关节功能评分;膝关节僵硬发生率。结果双侧切口双侧解剖钢板内固定组视觉模拟评分和Rasmussen膝关节功能评分、手术操作时间、手术失血、平均住院天数以及复杂胫骨平台骨折愈合时间、膝关节僵硬发生率和单侧锁定钢板内固定组比较有优势,P<0.05。结论复杂胫骨平台骨折患者实施双侧切口双侧解剖钢板内固定可获得较好效果。 相似文献
7.
《JACC: Cardiovascular Interventions》2022,15(7):741-750
ObjectivesThe aim of this study was to report 1-year clinical outcomes following commercial transcatheter left atrial appendage occlusion (LAAO) in the United States.BackgroundThe National Cardiovascular Data Registry LAAO Registry was initiated to meet a condition of Medicare coverage and allow the assessment of clinical outcomes. The 1-year rates of thromboembolic events after transcatheter LAAO in such a large cohort of “real-world” patients have not been previously reported.MethodsPatients entered into the National Cardiovascular Data Registry LAAO Registry for a Watchman procedure between January 1, 2016, and December 31, 2018, were included. The primary endpoint was ischemic stroke. Key secondary endpoints included the rate of ischemic stroke or systemic embolism, mortality, and major bleeding. Major bleeding was defined as any bleeding requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. The Kaplan-Meier method was used for 1-year estimates of cumulative event rates.ResultsThe study population consisted of 36,681 patients. The mean age was 76.0 ± 8.1 years, the mean CHA2DS2-VASc score was 4.8 ± 1.5, and the mean HAS-BLED score was 3.0 ± 1.1. Prior stroke was present in 25.5%, clinically relevant bleeding in 69.5%, and intracranial bleeding in 11.9%. Median follow-up was 374 days (IQR: 212-425 days). The Kaplan-Meier–estimated 1-year rate of ischemic stroke was 1.53% (95% CI: 1.39%-1.69%), the rate of ischemic stroke or systemic embolism was 2.19% (95% CI: 2.01%-2.38%), and the rate of mortality was 8.52% (95% CI: 8.19%-8.87%). The 1-year estimated rate of major bleeding was 6.93% (95% CI: 6.65%-7.21%). Most bleeding events occurred between discharge and 45 days following the procedure.ConclusionsThis study characterizes important outcomes in a national cohort of patients undergoing transcatheter LAAO in the United States. Clinicians and patients can integrate these data in shared decision making when considering this therapy. 相似文献
8.
9.
目的探讨附着龈重建应用于口腔种植修复中的临床效果。方法将本院于2016年10月-2018年10月期间收治的行口腔种植修复治疗的附着龈缺失患者82例作为研究资料,依据治疗方案分组,对照组为传统修复治疗方案,观察组采用附着龈重建治疗修复方案,各41例,评价两组术后不同阶段附着龈宽度、龈缘外形及附着点重建改善效果,并评价患者评价治疗满意度。结果术后3个月观察组患者附着龈宽度改善Ⅲ级率56.10%明显高于对照组0.00%,龈缘外形与附着点重建Ⅲ级率60.98%明显高于对照组0.00%(P <0.05);术后6个月观察组患者附着龈宽度改善Ⅲ级率75.61%明显高于对照组0.00%,龈缘外形与附着点重建Ⅲ级率73.17%明显高于对照组0.00%(P <0.05);观察组治疗满意度97.56%与对照组70.73%比较明显更高(P <0.05)。结论针对行口腔种植修复治疗的附着龈缺失患者采用附着龈重建治疗修复方案利于快速恢复附着龈增加宽度,改善龈缘外形及附着点重建效果,获得患者的高度满意度,治疗价值较高。 相似文献
10.
《Journal of the American Medical Directors Association》2020,21(3):439.e9-439.e13
Background/ObjectivesPolypharmacy and multimorbidity is a threat to older people; hence, listing approaches should support physicians to optimize medication. The FORTA (Fit fOR The Aged) classification of drug appropriateness for older people provides positive or negative labels: A (A-bsolutely), B (B-eneficial), C (C-areful), and D (D-on't). Based on these categories, FORTA-labeled drug lists were developed in 7 European countries or regions; the same approach was used to develop a U.S.-FORTA List reflecting the country-specific availability and usage of drugs.Design/SettingA 2-step Delphi-type approach was employed to add, remove, or relabel drugs from the listing proposal and to add or remove new indications. The proposal utilized the European (EURO)-FORTA list as template.ParticipantsEight US-based geriatricians/pharmacists served as raters. Measurements: Raters gave recommendations and comments on the list items.ResultsThe first U.S.-FORTA List contains 273 items aligned to 27 main indication groups; 30 drugs and drug groups were added, and 23 removed as being unavailable in the United States. The highest percentage of changes in FORTA labels as compared to the EURO-FORTA List occurred for sleep disorders associated with dementia (40%). In 8 indications, the labels for 11 items were different from the proposal. Thus, for the majority of the items (n = 232, 95.5%), the proposals were accepted by the US raters. Only 16 (6.6%) of the proposed items (n = 243) had to be re-evaluated in the second round as a result of inconsistent rating in the first round.Conclusions and ImplicationsThe U.S.-FORTA List addresses the appropriateness of drugs for older people in the United States reflecting country-specific availability, usage, and expert rating. As shown for the FORTA list in Europe, this listing approach is among the few that are clinically validated and improve well-being and geriatric outcomes. The U.S.-FORTA List now largely enhances the global availability of this approach. 相似文献